- Home
- HRTX vs OLMA Comparison
HRTX vs OLMA Comparison
Compare HRTX & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- OLMA
- Stock Information
- Founded
- HRTX 1983
- OLMA 2006
- Country
- HRTX United States
- OLMA United States
- Employees
- HRTX N/A
- OLMA N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- HRTX Health Care
- OLMA Health Care
- Exchange
- HRTX Nasdaq
- OLMA Nasdaq
- Market Cap
- HRTX 276.1M
- OLMA 378.9M
- IPO Year
- HRTX 1987
- OLMA 2020
- Fundamental
- Price
- HRTX $1.35
- OLMA $5.46
- Analyst Decision
- HRTX Strong Buy
- OLMA Strong Buy
- Analyst Count
- HRTX 2
- OLMA 5
- Target Price
- HRTX $4.50
- OLMA $24.00
- AVG Volume (30 Days)
- HRTX 2.6M
- OLMA 450.7K
- Earning Date
- HRTX 08-08-2025
- OLMA 08-11-2025
- Dividend Yield
- HRTX N/A
- OLMA N/A
- EPS Growth
- HRTX N/A
- OLMA N/A
- EPS
- HRTX N/A
- OLMA N/A
- Revenue
- HRTX $149,694,000.00
- OLMA N/A
- Revenue This Year
- HRTX $10.62
- OLMA N/A
- Revenue Next Year
- HRTX $12.99
- OLMA N/A
- P/E Ratio
- HRTX N/A
- OLMA N/A
- Revenue Growth
- HRTX 9.78
- OLMA N/A
- 52 Week Low
- HRTX $1.04
- OLMA $2.86
- 52 Week High
- HRTX $2.68
- OLMA $13.93
- Technical
- Relative Strength Index (RSI)
- HRTX 36.48
- OLMA 54.42
- Support Level
- HRTX $1.33
- OLMA $5.54
- Resistance Level
- HRTX $1.43
- OLMA $5.85
- Average True Range (ATR)
- HRTX 0.07
- OLMA 0.30
- MACD
- HRTX 0.02
- OLMA -0.01
- Stochastic Oscillator
- HRTX 45.45
- OLMA 51.79
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.